These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25850380)

  • 1. Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice.
    Shimizu S; Mizuguchi Y; Sobue A; Fujiwara M; Morimoto T; Ohno Y
    J Pharmacol Sci; 2015 Apr; 127(4):439-45. PubMed ID: 25850380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders.
    Tatara A; Shimizu S; Shin N; Sato M; Sugiuchi T; Imaki J; Ohno Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):252-9. PubMed ID: 22542492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms.
    Shimizu S; Mizuguchi Y; Tatara A; Kizu T; Andatsu S; Sobue A; Fujiwara M; Morimoto T; Ohno Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():86-91. PubMed ID: 23838274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F
    Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects.
    Ohno Y; Kunisawa N; Shimizu S
    Front Pharmacol; 2019; 10():1045. PubMed ID: 31607910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrapyramidal side-effect due to drug combination of risperidone and donepezil.
    Liu HC; Lin SK; Sung SM
    Psychiatry Clin Neurosci; 2002 Aug; 56(4):479. PubMed ID: 12109969
    [No Abstract]   [Full Text] [Related]  

  • 8. Extrapyramidal side effects in a patient treated with risperidone plus donepezil.
    Magnuson TM; Keller BK; Burke WJ
    Am J Psychiatry; 1998 Oct; 155(10):1458-9. PubMed ID: 9766783
    [No Abstract]   [Full Text] [Related]  

  • 9. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
    Thompson S; Lanctôt KL; Herrmann N
    Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers.
    Christoffersen CL; Meltzer LT
    Neuropsychopharmacology; 1998 May; 18(5):399-402. PubMed ID: 9536454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
    Kaufer DI
    Dement Geriatr Cogn Disord; 2004; 17 Suppl 1():32-9. PubMed ID: 14676467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.
    Hernandez RK; Farwell W; Cantor MD; Lawler EV
    J Am Geriatr Soc; 2009 Nov; 57(11):1997-2003. PubMed ID: 19793162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study.
    Rege S; Carnahan RM; Johnson ML; Chen H; Holmes HM; Aparasu RR
    Drugs Aging; 2021 Jun; 38(6):493-502. PubMed ID: 33763822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Featured CME topic: dementia. Medication update.
    Slagle MA
    South Med J; 2001 Jul; 94(7):678-81. PubMed ID: 11531174
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
    Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors.
    Ohno Y; Imaki J; Mae Y; Takahashi T; Tatara A
    Neuropharmacology; 2011; 60(2-3):201-8. PubMed ID: 20813116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Alzheimer drugs: life-threatening adverse effects.
    Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17326275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test.
    Ohno Y; Shimizu S; Imaki J; Ishihara S; Sofue N; Sasa M; Kawai Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1302-7. PubMed ID: 18495311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.